MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 154 filers reported holding MERSANA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $20,973,750 | -32.4% | 6,375,000 | -15.6% | 0.28% | -38.0% |
| Q1 2023 | $31,030,500 | -29.9% | 7,550,000 | 0.0% | 0.46% | -30.4% |
| Q4 2022 | $44,243,000 | -13.3% | 7,550,000 | 0.0% | 0.66% | -29.9% |
| Q3 2022 | $51,038,000 | +46.3% | 7,550,000 | 0.0% | 0.94% | +36.9% |
| Q2 2022 | $34,881,000 | +28.6% | 7,550,000 | +11.0% | 0.69% | +39.2% |
| Q1 2022 | $27,132,000 | -35.9% | 6,800,000 | 0.0% | 0.50% | -31.2% |
| Q4 2021 | $42,296,000 | -34.0% | 6,800,000 | 0.0% | 0.72% | -28.5% |
| Q3 2021 | $64,124,000 | -30.6% | 6,800,000 | 0.0% | 1.01% | -37.3% |
| Q2 2021 | $92,344,000 | -16.1% | 6,800,000 | 0.0% | 1.61% | -15.5% |
| Q1 2021 | $110,024,000 | -39.2% | 6,800,000 | 0.0% | 1.90% | -39.0% |
| Q4 2020 | $180,948,000 | +42.9% | 6,800,000 | 0.0% | 3.12% | +73.2% |
| Q3 2020 | $126,616,000 | -16.8% | 6,800,000 | +4.6% | 1.80% | -40.2% |
| Q2 2020 | $152,100,000 | – | 6,500,000 | – | 3.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |